BIOAGE LABS, INC. (BIOA) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$29.33M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$25.38M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$23.14M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$24.77M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$29.33M | (m) | $2.45M | (m) | $328.00K* | -$19.26M* | (m) | $24.36M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$25.38M | (m) | $2.77M | (m) | $26.00K | -$24.05M | (m) | $20.41M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$23.14M | (m) | $2.05M | (m) | $22.00K* | -$16.04M* | (m) | $18.51M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$24.77M | (m) | $2.41M | (m) | $159.00K* | -$19.97M* | (m) | $19.84M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$16.45M | (m) | $1.45M | (m) | $426.00K | -$17.36M | (m) | $11.11M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$24.75M | (m) | $0.00 | (m) | $305.00K* | -$14.93M* | (m) | $20.02M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$15.27M | (m) | $0.00 | (m) | $35.00K* | -$15.78M* | (m) | $10.47M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$12.81M | (m) | (m) | (m) | $0.00 | -$15.67M | (m) | $9.32M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$9.89M | (m) | (m) | (m) | (m) | (m) | (m) | $6.53M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$92.78M | (m) | $8.99M | (m) | $719.00K | -$81.63M | (m) | $73.97M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$78.19M | (m) | $0.00 | (m) | $366.00K | -$51.52M | (m) | $59.04M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$48.40M | (m) | (m) | (m) | $166.00K | -$37.36M | (m) | $33.89M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |